Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with psychological burden among informal caregivers in outpatient palliative care: a prospective observational study of patient-caregiver dyads in Germany.

BMJ open·2026
Same author

Factors Associated with Time to Sarcoma Diagnosis: Results from a Global Cross-Sectional Survey by the Sarcoma Patient Advocacy Global Network (SPAGN).

Cancers·2026
Same author

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group.

Journal of cancer research and clinical oncology·2026
Same author

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.

Cancer·2026
Same author

The Health-Related Quality of Life of German Desmoid Patients: Results from the PROSa-DES and PROSa Study.

Cancers·2026

Related Experiment Video

Updated: Aug 9, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K

Electronic Patient Reported Outcome (ePRO) Measures in Patients with Soft Tissue Sarcoma (STS) Receiving Palliative

Silvia Hofer1, Leopold Hentschel2, Stephan Richter3

  • 1Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland.

Cancers
|February 25, 2023
PubMed
Summary

The PazoQoL study found that patient-reported outcomes reliably tracked quality of life during cancer therapy. Time Trade-off (TTO) assessments revealed patient expectations often exceeded therapy benefits, highlighting a need for better outcome communication.

Keywords:
electronic patient reported outcomehealth related quality of lifepalliative treatmentrandomized controlled trialsoft tissue sarcoma

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

Related Experiment Videos

Last Updated: Aug 9, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

Area of Science:

  • Oncology
  • Patient-Reported Outcomes
  • Health Economics

Background:

  • Assessing health-related quality of life (HRQoL) is crucial for cancer therapy evaluation.
  • Pazopanib and physician-preferred chemotherapy represent common treatment options.
  • Continuous monitoring of patient experience can inform treatment adjustments.

Purpose of the Study:

  • To continuously assess global health-related quality of life (HRQoL) during pazopanib or chemotherapy.
  • To evaluate the reliability and utility of electronic patient-reported outcomes (ePRO) for early detection of deterioration.
  • To compare the effectiveness of Cancer Therapy Satisfaction Questionnaire (CTSQ) and Time Trade-off (TTO) in assessing patient benefit.

Main Methods:

  • Prospective, randomized, controlled, multicenter study design.
  • Utilized electronic patient-reported outcomes (ePRO) for continuous HRQoL assessment over 9 weeks.
  • Administered CTSQ and TTO questionnaires for patient-reported outcome measurement.

Main Results:

  • ePROs were reliably completed by patients at home, enabling early detection of deterioration.
  • CTSQ showed high variability and decline over 9 weeks.
  • TTO demonstrated that patient expectations regarding life prolongation and side effect profiles often exceeded actual therapy benefits.

Conclusions:

  • Continuous ePRO monitoring is feasible and valuable for managing cancer therapy.
  • TTO is an effective method for assessing individual patient benefit from cancer therapy.
  • Findings suggest a discrepancy between patient expectations and therapy outcomes, impacting satisfaction.